Answers are grounded in this paper and cite their sources.
Randomized trial demonstrates improved bone preservation with advanced platelet-rich fibrin after molar extraction, indicating enhanced regenerative benefits over concentrated growth factors.
While platelet concentrates, such as concentrated growth factors (CGF) and advanced platelet-rich fibrin (A-PRF), are promising autologous biomaterials, direct evidence comparing their efficacy for alveolar ridge preservation (ARP) is limited. This trial clinically and radiographically compared the effects of A-PRF and CGF on postoperative healing and ARP following impacted lower third molar extraction. A randomized, controlled trial was conducted with 60 patients, with impacted lower third molars were randomly allocated (1:1:1) into three groups (n = 20 each): A-PRF, CGF, and a natural-healing control. Clinical parameters were assessed as follows: postoperative pain and facial swelling were assessed on days 1, 3, and 7; wound healing was scored on day 7. Radiographic parameters were assessed by cone-beam computed tomography (CBCT) at baseline and at 3 months. Measurements included buccal and lingual alveolar bone height and alveolar ridge width. On the first postoperative day, pain and facial swelling were comparable across groups. By the third day, A-PRF and CGF showed significantly lower pain (1.0±0.7; 1.6±1.1) and swelling (11.2±4.7; 12.0±4.8) than the control (3.2±1.3; 36.9±11.7; P<0.001). By the seventh day, pain resolved completely in both interventions. Wound healing was significantly better for both CGF (3.6±0.5) and A-PRF (3.5±0.5) than the control (3.1±0.3; P=0.006), with no difference between interventions. Radiographically, the control group exhibited bone loss across all dimensions. Both CGF and A-PRF preserved alveolar bone width comparably (A-PRF: +0.38 ± 0.92 mm; CGF: +0.18 ± 0.79 mm; both vs. control: P ≤ 0.014). For buccal wall height, A-PRF demonstrated a significant mean gain (+1.32 ± 0.72 mm) over both the control (−0.07 ± 1.12 mm; P < 0.001) and CGF (+0.01 ± 1.6 mm; P = 0.012). For lingual wall height, A-PRF (+0.57 ± 0.86 mm) was significantly superior to the control (−0.06 ± 0.69 mm; P = 0.001), whereas CGF (+0.24 ± 0.98 mm) showed only a non-significant improvement. Both CGF and A-PRF significantly reduced pain and swelling and improved soft-tissue healing versus controls. Radiographically, both interventions preserved alveolar bone width. However, A-PRF preserved buccal wall height significantly better than CGF and control groups. This trial was retrospectively registered under the TCTR identification number TCTR20251028003 on 28 October 2025.
No takes yet. Share an insight, caveat, or question.
Sallam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: